Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata; Ann Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang Hyub Han; Yoghesh K. Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei Jer Chen; Cosmas Rinaldi A. Lesmana; Laurentius A. Lesmana; Rino A. Gani; Shuntaro Obi; A. Kadir Dokmeci; Shiv Kumar Sarin

doi:10.1007/s12072-017-9799-9

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Masao Omata, Ann Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir DokmeciShiv Kumar Sarin

Department of Internal Medicine

Research output: Contribution to journal › Editorial › peer-review

1213 Citations (Scopus)

Abstract

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

Original language	English
Pages (from-to)	317-370
Number of pages	54
Journal	Hepatology International
Volume	11
Issue number	4
DOIs	https://doi.org/10.1007/s12072-017-9799-9
Publication status	Published - 2017 Jul 1

Bibliographical note

Funding Information:
Masao Omata received fees for being a speaker, consultant, and advisory board member from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, Merck Serono, and Zeria. Ann-Lii Cheng received consultant fees from Novartis, Merck Serono, Eisai, Merck Sharp and Dohme, ONXEO, Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical. Norihiro Kokudo received research grants from Dainippon Sumitomo, Astellas, and Taiho. Masatoshi Kudo received lecture fees from Bayer, Eisai, Merck Sharp and Dohme, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Dainippon Sumitomo, Daiichi Sankyo, Merck Sharp and Dohme, Eisai, Bayer, and AbbVie, and consulting or advisory fees from Kowa, Merck Sharp and Dohme, Bristol-Myers Squibb, Bayer, Chugai, and Taiho. Jidong Jia received consultation and speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Novartis, and Roche. Sadahisa Ogasawara received a consulting or advisory fee from Bayer and Eisai and honoraria from Bayer and Eisai. Jeong Min Lee, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin declare that they have no conflict of interest.

Publisher Copyright:
© 2017, The Author(s).

All Science Journal Classification (ASJC) codes

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-017-9799-9

Cite this

Omata, M., Cheng, A. L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K. H., Chawla, Y. K., Shiina, S., Jafri, W., Payawal, D. A., Ohki, T., Ogasawara, S., Chen, P. J., Lesmana, C. R. A., Lesmana, L. A., Gani, R. A., Obi, S., ... Sarin, S. K. (2017). Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 11(4), 317-370. https://doi.org/10.1007/s12072-017-9799-9

@article{5ef94cd88cd44dc4912f13c63beee136,

title = "Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update",

abstract = "There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.",

author = "Masao Omata and Cheng, {Ann Lii} and Norihiro Kokudo and Masatoshi Kudo and Lee, {Jeong Min} and Jidong Jia and Ryosuke Tateishi and Han, {Kwang Hyub} and Chawla, {Yoghesh K.} and Shuichiro Shiina and Wasim Jafri and Payawal, {Diana Alcantara} and Takamasa Ohki and Sadahisa Ogasawara and Chen, {Pei Jer} and Lesmana, {Cosmas Rinaldi A.} and Lesmana, {Laurentius A.} and Gani, {Rino A.} and Shuntaro Obi and Dokmeci, {A. Kadir} and Sarin, {Shiv Kumar}",

note = "Funding Information: Masao Omata received fees for being a speaker, consultant, and advisory board member from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, Merck Serono, and Zeria. Ann-Lii Cheng received consultant fees from Novartis, Merck Serono, Eisai, Merck Sharp and Dohme, ONXEO, Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical. Norihiro Kokudo received research grants from Dainippon Sumitomo, Astellas, and Taiho. Masatoshi Kudo received lecture fees from Bayer, Eisai, Merck Sharp and Dohme, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Dainippon Sumitomo, Daiichi Sankyo, Merck Sharp and Dohme, Eisai, Bayer, and AbbVie, and consulting or advisory fees from Kowa, Merck Sharp and Dohme, Bristol-Myers Squibb, Bayer, Chugai, and Taiho. Jidong Jia received consultation and speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Novartis, and Roche. Sadahisa Ogasawara received a consulting or advisory fee from Bayer and Eisai and honoraria from Bayer and Eisai. Jeong Min Lee, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin declare that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2017",

month = jul,

day = "1",

doi = "10.1007/s12072-017-9799-9",

language = "English",

volume = "11",

pages = "317--370",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "4",

}

Omata, M, Cheng, AL, Kokudo, N, Kudo, M, Lee, JM, Jia, J, Tateishi, R, Han, KH, Chawla, YK, Shiina, S, Jafri, W, Payawal, DA, Ohki, T, Ogasawara, S, Chen, PJ, Lesmana, CRA, Lesmana, LA, Gani, RA, Obi, S, Dokmeci, AK & Sarin, SK 2017, 'Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update', Hepatology International, vol. 11, no. 4, pp. 317-370. https://doi.org/10.1007/s12072-017-9799-9

TY - JOUR

T1 - Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma

T2 - a 2017 update

AU - Omata, Masao

AU - Cheng, Ann Lii

AU - Kokudo, Norihiro

AU - Kudo, Masatoshi

AU - Lee, Jeong Min

AU - Jia, Jidong

AU - Tateishi, Ryosuke

AU - Han, Kwang Hyub

AU - Chawla, Yoghesh K.

AU - Shiina, Shuichiro

AU - Jafri, Wasim

AU - Payawal, Diana Alcantara

AU - Ohki, Takamasa

AU - Ogasawara, Sadahisa

AU - Chen, Pei Jer

AU - Lesmana, Cosmas Rinaldi A.

AU - Lesmana, Laurentius A.

AU - Gani, Rino A.

AU - Obi, Shuntaro

AU - Dokmeci, A. Kadir

AU - Sarin, Shiv Kumar

N1 - Funding Information: Masao Omata received fees for being a speaker, consultant, and advisory board member from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, Merck Serono, and Zeria. Ann-Lii Cheng received consultant fees from Novartis, Merck Serono, Eisai, Merck Sharp and Dohme, ONXEO, Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical. Norihiro Kokudo received research grants from Dainippon Sumitomo, Astellas, and Taiho. Masatoshi Kudo received lecture fees from Bayer, Eisai, Merck Sharp and Dohme, and Ajinomoto, research grants from Chugai, Otsuka, Takeda, Dainippon Sumitomo, Daiichi Sankyo, Merck Sharp and Dohme, Eisai, Bayer, and AbbVie, and consulting or advisory fees from Kowa, Merck Sharp and Dohme, Bristol-Myers Squibb, Bayer, Chugai, and Taiho. Jidong Jia received consultation and speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Novartis, and Roche. Sadahisa Ogasawara received a consulting or advisory fee from Bayer and Eisai and honoraria from Bayer and Eisai. Jeong Min Lee, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, and Shiv Kumar Sarin declare that they have no conflict of interest. Publisher Copyright: © 2017, The Author(s).

PY - 2017/7/1

Y1 - 2017/7/1

N2 - There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

AB - There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

UR - http://www.scopus.com/inward/record.url?scp=85020518973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020518973&partnerID=8YFLogxK

U2 - 10.1007/s12072-017-9799-9

DO - 10.1007/s12072-017-9799-9

M3 - Editorial

C2 - 28620797

AN - SCOPUS:85020518973

SN - 1936-0533

VL - 11

SP - 317

EP - 370

JO - Hepatology International

JF - Hepatology International

IS - 4

ER -

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this